RPRXRoyalty Pharma plc Class A Ordinary Shares

CSNasdaq (XNAS)·USD

Identity

Security key: 21117
Ticker: RPRX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-06-16
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: RPRX

Detail

Enriched 2026-08-14 20:47

Market cap: $26,369,324,311.68
Shares outstanding (class): 445,277,344
Shares outstanding (weighted): 445,277,344
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 100
Location: NEW YORK, NY
Homepage: https://www.royaltypharma.com
Description: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Market cap and share counts drift.

Funds holding this security

220 funds · 224 positions · $3.00B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
New Perspective Fund New Perspective Fund	—	$942.41M	0.62%	19,645,749 NS	TICKER
GROWTH PORTFOLIO MORGAN STANLEY INSTITUTIONAL FUND INC	—	$249.93M	7.60%	5,210,200 NS	TICKER
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$201.81M	0.25%	4,207,099 NS	TICKER
VictoryShares Free Cash Flow ETF Victory Portfolios II	VFLO	$144.78M	2.35%	3,018,039 NS	TICKER
Patient Opportunity Trust Advisor Managed Portfolios	—	$119.92M	6.91%	2,500,000 NS	TICKER
Morgan Stanley Discovery Portfolio Brighthouse Funds Trust I	—	$91.18M	8.14%	1,900,841 NS	TICKER
Morgan Stanley Insight Fund Morgan Stanley Insight Fund	—	$82.26M	7.35%	1,714,764 NS	TICKER
iShares Russell Mid-Cap ETF iShares Trust	IWR	$70.61M	0.15%	1,471,943 NS	TICKER
VANGUARD GLOBAL EQUITY FUND VANGUARD HORIZON FUNDS	—	$70.54M	1.01%	1,470,561 NS	TICKER
Growth Fund AMERICAN FUNDS INSURANCE SERIES	—	$66.70M	0.13%	1,390,366 NS	TICKER
Discovery Portfolio MORGAN STANLEY INSTITUTIONAL FUND TRUST	—	$64.44M	8.67%	1,343,329 NS	TICKER
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$59.57M	0.55%	1,241,743 NS	TICKER
iShares U.S. Pharmaceuticals ETF iShares Trust	IHE	$47.07M	4.70%	981,152 NS	TICKER
iShares Russell 1000 Value ETF iShares Trust	IWD	$42.72M	0.06%	890,554 NS	TICKER
Growth Portfolio MORGAN STANLEY VARIABLE INSURANCE FUND INC.	—	$40.54M	7.87%	845,182 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERRPRX
CIK0001802768
ISINGB00BMVP7Y09
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Royalty Pharma is a pharmaceutical royalty company, classified under healthcare and pharmaceuticals per its SIC code.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.